Chromosome News and Research

Latest Chromosome News and Research

Research findings may lead to new treatment strategies for Ewing sarcoma

The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes - both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. These findings by Massachusetts General Hospital investigators, published in the November issue of Cancer Cell, may lead to new therapies targeting these aberrant mechanisms.

18 Dec 2014

Tel Aviv University study throws spotlight on gene mutation responsible for premature ovarian failure

Premature ovarian failure, also known as primary ovarian insufficiency (POI), affects 1% of all women worldwide. In most cases, the exact cause of the condition, which is often associated with infertility, is difficult to determine.

18 Dec 2014

Mitochondrial DNA may predict overall risk of frailty, death

New research from The Johns Hopkins University suggests that the amount of mitochondrial DNA (mtDNA) found in peoples’ blood directly relates to how frail they are medically. This DNA may prove to be a useful predictor of overall risk of frailty and death from any cause 10 to 15 years before symptoms appear.

17 Dec 2014

Experts expose fundamental role of chaos and complexity in biological information processing

The interdisciplinary approach to problems that till recently were addressed in the hermetic framework of distinct disciplines such as physics, informatics, biology or sociology constitutes today one of the most active and innovative areas of science, where fundamental issues meet problems of everyday concern.

14 Dec 2014

TGen uncovers way to track cause of neurological disorder in a young girl

Using a basic genetic difference between men and women, the Translational Genomics Research Institute has uncovered a way to track down the source of a neurological disorder in a young girl.

14 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

Higher human exposure to metal cadmium can lead to shorter telomeres

A new study led by a researcher at Milken Institute School of Public Health at the George Washington University looks at the metal cadmium and finds that higher human exposure can lead to significantly shorter telomeres, bits of DNA at the ends of chromosomes that are associated with cardiovascular disease, diabetes and other diseases of old age.

11 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Findings open new avenues for research to predict risk of therapy-related AML

For a small percentage of cancer patients, treatment aimed at curing the disease leads to a form of leukemia with a poor prognosis. Conventional thinking goes that chemotherapy and radiation therapy induce a barrage of damaging genetic mutations that kill cancer cells yet inadvertently spur the development of acute myeloid leukemia (AML), a blood cancer.

8 Dec 2014

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand.

8 Dec 2014

Baylor-led researchers identify gene linked to familial glioma

An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease.

8 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

A therapy that liberates the immune system to attack cancer cells drove Hodgkin lymphoma (HL) into complete or partial remission in fully 87 percent of patients with resistant forms of the disease who participated in an early-phase clinical trial, investigators at Dana-Farber Cancer Institute and partnering institutions report in a study published today in the New England Journal of Medicine and simultaneously presented at the annual meeting of the American Society of Hematology in San Francisco.

7 Dec 2014

Study provides insights into genetic underpinnings of childhood epilepsies

Technological advances in genetic analysis have uncovered changes in single genes that account for a surprising number of infantile and early-childhood epilepsies. Though some of the affected genes have been identified, the physical manifestations of these alterations remain largely uncharacterized.

7 Dec 2014

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

MorphoSys AG and Xencor Inc. today announced the publication of final results of a Phase 1/2a trial evaluating MOR208 (formerly XmAb5574) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).

7 Dec 2014

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM).

7 Dec 2014

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Cancers are due to genetic aberrations in certain cells that gain the ability to divide indefinitely. This proliferation of sick cells generates tumors, which gradually invade healthy tissue. Therefore, current therapies essentially seek to destroy cancer cells to stop their proliferation. Through high-throughput genetic sequencing of glioblastoma cells, one of the most deadly brain tumors, a team of geneticists from the University of Geneva's (UNIGE) Faculty of Medicine discovered that some of these mutations are caused by supplemental extrachromosomal DNA fragments, called double minutes, which enable cancer cells to better adapt to their environment and therefore better resist to treatments meant to destroy them.

6 Dec 2014

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Pharmacyclics, Inc. today announced the launch of informCLL, a large, observational, prospective registry that will explore the natural history of chronic lymphocytic leukemia (CLL), examine how IMBRUVICA (ibrutinib) and other approved targeted therapies are being used to treat patients with CLL, and provide a comparison to treatments using conventional chemoimmunotherapy (CIT).

5 Dec 2014

Chromosome News and Research

Latest Chromosome News and Research

Research findings may lead to new treatment strategies for Ewing sarcoma

Tel Aviv University study throws spotlight on gene mutation responsible for premature ovarian failure

Mitochondrial DNA may predict overall risk of frailty, death

Experts expose fundamental role of chaos and complexity in biological information processing

TGen uncovers way to track cause of neurological disorder in a young girl

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Higher human exposure to metal cadmium can lead to shorter telomeres

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Findings open new avenues for research to predict risk of therapy-related AML

Researchers report promising outcomes from clinical trial in patients with dyskeratosis congenita

Baylor-led researchers identify gene linked to familial glioma

Novel targeted therapies and treatment combinations for leukemia

Breakthrough therapy shows promise in resistant forms of Hodgkin lymphoma

Study provides insights into genetic underpinnings of childhood epilepsies

MorphoSys, Xencor announce final results from MOR208 Phase 1/2a trial in patients with CLL/SLL

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

Scientists suspect role of mini-chromosomes in cancers, diseases caused by gene mutations

Pharmacyclics launches informCLL registry to explore natural history of CLL patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chromosome News and Research

Latest Chromosome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in